Ultragenyx Pharma (RARE) PT Raised to $75 at Cowen

Cowen analyst Yaron Werber raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $75.00 (from $59.00) while maintaining a Outperform rating.

The analyst commented, "We are making updates to our model to reflect preannounced Q4 results, FY20 financial guidance, and are now adding revenues for DTX301 & DTX401. Our new PT of $75 (+$16) is based on 35x (unchanged) $2.85E (+$0.98) ‘24 EPS discounted by 10% (unchanged)."

You May Also Be Interested In

• Walker & Dunlop (WD) PT Lowered to $55 at Citizens Amid Interest Rate Headwinds
• Morgan Stanley Upgrades Audinate Group Ltd (AD8:AU) to Overweight
• JPMorgan Double Upgrades Hemnet Group AB (HEM:SS) to Overweight